The University of Southampton
University of Southampton Institutional Repository

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Background: given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZeneca), two mRNA vaccines (BNT162b2 [BNT], Pfizer-BioNTech, and mRNA-1273 [m1273], Moderna) and a nanoparticle vaccine containing SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant (NVX-CoV2373 [NVX], Novavax).

Methods: Com-COV2 is a single-blind, randomised, non-inferiority trial in which adults aged 50 years and older, previously immunised with a single dose of ChAd or BNT in the community, were randomly assigned (in random blocks of three and six) within these cohorts in a 1:1:1 ratio to receive a second dose intramuscularly (8-12 weeks after the first dose) with the homologous vaccine, m1273, or NVX. The primary endpoint was the geometric mean ratio (GMR) of serum SARS-CoV-2 anti-spike IgG concentrations measured by ELISA in heterologous versus homologous schedules at 28 days after the second dose, with a non-inferiority criterion of the GMR above 0·63 for the one-sided 98·75% CI. The primary analysis was on the per-protocol population, who were seronegative at baseline. Safety analyses were done for all participants who received a dose of study vaccine. The trial is registered with ISRCTN, number 27841311.

Findings: between April 19 and May 14, 2021, 1072 participants were enrolled at a median of 9·4 weeks after receipt of a single dose of ChAd (n=540, 47% female) or BNT (n=532, 40% female). In ChAd-primed participants, geometric mean concentration (GMC) 28 days after a boost of SARS-CoV-2 anti-spike IgG in recipients of ChAd/m1273 (20 114 ELISA laboratory units [ELU]/mL [95% CI 18 160 to 22 279]) and ChAd/NVX (5597 ELU/mL [4756 to 6586]) was non-inferior to that of ChAd/ChAd recipients (1971 ELU/mL [1718 to 2262]) with a GMR of 10·2 (one-sided 98·75% CI 8·4 to ∞) for ChAd/m1273 and 2·8 (2·2 to ∞) for ChAd/NVX, compared with ChAd/ChAd. In BNT-primed participants, non-inferiority was shown for BNT/m1273 (GMC 22 978 ELU/mL [95% CI 20 597 to 25 636]) but not for BNT/NVX (8874 ELU/mL [7391 to 10 654]), compared with BNT/BNT (16 929 ELU/mL [15 025 to 19 075]) with a GMR of 1·3 (one-sided 98·75% CI 1·1 to ∞) for BNT/m1273 and 0·5 (0·4 to ∞) for BNT/NVX, compared with BNT/BNT; however, NVX still induced an 18-fold rise in GMC 28 days after vaccination. There were 15 serious adverse events, none considered related to immunisation.

Interpretation: heterologous second dosing with m1273, but not NVX, increased transient systemic reactogenicity compared with homologous schedules. Multiple vaccines are appropriate to complete primary immunisation following priming with BNT or ChAd, facilitating rapid vaccine deployment globally and supporting recognition of such schedules for vaccine certification.

Funding: UK Vaccine Task Force, Coalition for Epidemic Preparedness Innovations (CEPI), and National Institute for Health Research. NVX vaccine was supplied for use in the trial by Novavax.

0140-6736
36-49
Stuart, Arabella S V
33deeaa1-85ee-45fd-8074-2f63012b6f8d
Shaw, Robert H
51ce854b-8895-4e04-974c-a92f00dcb390
Liu, Xinxue
9167ef53-49a2-4100-a050-87569421468f
Greenland, Melanie
f1ad44ed-4d20-4800-9d91-89a103a46182
Aley, Parvinder K
47682c89-e7f3-481a-9176-23bb4053ba36
Andrews, Nick J
a262c189-ff23-45de-822c-213d6dcedad9
Cameron, J C
b8ee674b-648c-44eb-870c-d0eda7eef901
Charlton, Sue
77a47a88-9326-4b27-8828-ff8ce24839ac
Clutterbuck, Elizabeth A
db4945e9-ca8e-44f8-8030-4c0160956e71
Collins, Andrea M
7c571856-429e-48f9-9e72-d70911ac9509
Darton, Tom
30f7ff5a-2ab3-4e28-99c5-2cff04f3314a
Dinesh, Tanya
5d4db0cf-3ba7-468a-90da-c801afa3f15f
Duncan, Christopher J A
3d260353-99a0-42ee-b45e-4a4bfaec00e6
England, Anna
590a306a-2173-4799-80b8-d09e44854f59
Faust, Saul N
f97df780-9f9b-418e-b349-7adf63e150c1
Ferreira, Daniela M
492eac42-4e06-406e-a164-db091574ac65
Finn, Adam
1c9de3fb-4f8b-4ce4-812e-c93506254d34
Goodman, Anna L
6541cbb8-783d-4470-8235-a6595320c267
Green, Christopher A
9b0dcffd-56be-49f7-bfdf-d11195cde1a3
Hallis, Bassam
45ed9114-5656-4c85-9d9d-9eaf6420eda9
Heath, Paul T
b9b6e0e4-6bd0-4c16-b9f6-607b00137fe4
Hill, Helen
45e6001e-508f-436f-b5e3-1ba80c3e9229
Horsington, Bryn M
139169e5-c68b-4e84-94f7-671d74717e90
Lambe, Teresa
d5fd6770-9ef0-45a9-a23a-9a7d865009a6
Lazarus, Rajeka
9cef06db-d282-42b9-85fe-5ae26bdf6813
Libri, Vincenzo
cec4fc4f-68e0-4081-a12a-ec1a68ab94a2
Lillie, Patrick J
3068afd9-e2bd-4c75-8ad3-e95b412f3456
Mujadidi, Yama F
bffb5a37-2ab0-4883-9001-c00b4e996c8c
Payne, Ruth
d42dc1e1-6563-4586-bab6-692f5a5b9d2f
Plested, Emma L
7af2cc98-f996-4bca-bfab-ff02982a9780
Provstgaard-Morys, Samuel
3f808a53-eded-4000-94a6-7e241826337b
Ramasamy, Maheshi N
ae42fa67-f3e2-430a-81da-92d601b96b79
Ramsay, Mary
69ca3a9b-df7c-4ddb-9527-8c94adbf3880
Read, Robert C
b5caca7b-0063-438a-b703-7ecbb6fc2b51
Robinson, Hannah
5db3b2f0-c4a0-4cf3-a0e7-11a85972e000
Screaton, Gavin R
5f3f34e7-588d-4352-9e56-62e32fa10611
Singh, Nisha
cf2bc6b0-8d3d-44c8-98e6-05005334112a
Turner, David P J
f0be879b-553c-44d4-ac4d-4aaf90adb36e
Turner, Paul J
22cee218-a226-4300-aad1-b9a77ca65915
Vichos, Iason
1394031b-13e7-4e9c-8c0c-c7e16e41a5f8
White, Rachel
26e3f8c1-fea8-4751-b75e-d6e2078a8206
Nguyen-Van-Tam, Jonathan S
1aac2164-f614-4c82-87f9-e123817bf128
Snape, Matthew D
ea21c8b9-e907-4914-9052-ae9eb56f54d7
Com-COV2 Study Group
Stuart, Arabella S V
33deeaa1-85ee-45fd-8074-2f63012b6f8d
Shaw, Robert H
51ce854b-8895-4e04-974c-a92f00dcb390
Liu, Xinxue
9167ef53-49a2-4100-a050-87569421468f
Greenland, Melanie
f1ad44ed-4d20-4800-9d91-89a103a46182
Aley, Parvinder K
47682c89-e7f3-481a-9176-23bb4053ba36
Andrews, Nick J
a262c189-ff23-45de-822c-213d6dcedad9
Cameron, J C
b8ee674b-648c-44eb-870c-d0eda7eef901
Charlton, Sue
77a47a88-9326-4b27-8828-ff8ce24839ac
Clutterbuck, Elizabeth A
db4945e9-ca8e-44f8-8030-4c0160956e71
Collins, Andrea M
7c571856-429e-48f9-9e72-d70911ac9509
Darton, Tom
30f7ff5a-2ab3-4e28-99c5-2cff04f3314a
Dinesh, Tanya
5d4db0cf-3ba7-468a-90da-c801afa3f15f
Duncan, Christopher J A
3d260353-99a0-42ee-b45e-4a4bfaec00e6
England, Anna
590a306a-2173-4799-80b8-d09e44854f59
Faust, Saul N
f97df780-9f9b-418e-b349-7adf63e150c1
Ferreira, Daniela M
492eac42-4e06-406e-a164-db091574ac65
Finn, Adam
1c9de3fb-4f8b-4ce4-812e-c93506254d34
Goodman, Anna L
6541cbb8-783d-4470-8235-a6595320c267
Green, Christopher A
9b0dcffd-56be-49f7-bfdf-d11195cde1a3
Hallis, Bassam
45ed9114-5656-4c85-9d9d-9eaf6420eda9
Heath, Paul T
b9b6e0e4-6bd0-4c16-b9f6-607b00137fe4
Hill, Helen
45e6001e-508f-436f-b5e3-1ba80c3e9229
Horsington, Bryn M
139169e5-c68b-4e84-94f7-671d74717e90
Lambe, Teresa
d5fd6770-9ef0-45a9-a23a-9a7d865009a6
Lazarus, Rajeka
9cef06db-d282-42b9-85fe-5ae26bdf6813
Libri, Vincenzo
cec4fc4f-68e0-4081-a12a-ec1a68ab94a2
Lillie, Patrick J
3068afd9-e2bd-4c75-8ad3-e95b412f3456
Mujadidi, Yama F
bffb5a37-2ab0-4883-9001-c00b4e996c8c
Payne, Ruth
d42dc1e1-6563-4586-bab6-692f5a5b9d2f
Plested, Emma L
7af2cc98-f996-4bca-bfab-ff02982a9780
Provstgaard-Morys, Samuel
3f808a53-eded-4000-94a6-7e241826337b
Ramasamy, Maheshi N
ae42fa67-f3e2-430a-81da-92d601b96b79
Ramsay, Mary
69ca3a9b-df7c-4ddb-9527-8c94adbf3880
Read, Robert C
b5caca7b-0063-438a-b703-7ecbb6fc2b51
Robinson, Hannah
5db3b2f0-c4a0-4cf3-a0e7-11a85972e000
Screaton, Gavin R
5f3f34e7-588d-4352-9e56-62e32fa10611
Singh, Nisha
cf2bc6b0-8d3d-44c8-98e6-05005334112a
Turner, David P J
f0be879b-553c-44d4-ac4d-4aaf90adb36e
Turner, Paul J
22cee218-a226-4300-aad1-b9a77ca65915
Vichos, Iason
1394031b-13e7-4e9c-8c0c-c7e16e41a5f8
White, Rachel
26e3f8c1-fea8-4751-b75e-d6e2078a8206
Nguyen-Van-Tam, Jonathan S
1aac2164-f614-4c82-87f9-e123817bf128
Snape, Matthew D
ea21c8b9-e907-4914-9052-ae9eb56f54d7

Stuart, Arabella S V, Shaw, Robert H, Liu, Xinxue, Greenland, Melanie, Aley, Parvinder K and Andrews, Nick J , Com-COV2 Study Group (2022) Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. The Lancet, 399 (10319), 36-49. (doi:10.1016/S0140-6736(21)02718-5).

Record type: Article

Abstract

Background: given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZeneca), two mRNA vaccines (BNT162b2 [BNT], Pfizer-BioNTech, and mRNA-1273 [m1273], Moderna) and a nanoparticle vaccine containing SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant (NVX-CoV2373 [NVX], Novavax).

Methods: Com-COV2 is a single-blind, randomised, non-inferiority trial in which adults aged 50 years and older, previously immunised with a single dose of ChAd or BNT in the community, were randomly assigned (in random blocks of three and six) within these cohorts in a 1:1:1 ratio to receive a second dose intramuscularly (8-12 weeks after the first dose) with the homologous vaccine, m1273, or NVX. The primary endpoint was the geometric mean ratio (GMR) of serum SARS-CoV-2 anti-spike IgG concentrations measured by ELISA in heterologous versus homologous schedules at 28 days after the second dose, with a non-inferiority criterion of the GMR above 0·63 for the one-sided 98·75% CI. The primary analysis was on the per-protocol population, who were seronegative at baseline. Safety analyses were done for all participants who received a dose of study vaccine. The trial is registered with ISRCTN, number 27841311.

Findings: between April 19 and May 14, 2021, 1072 participants were enrolled at a median of 9·4 weeks after receipt of a single dose of ChAd (n=540, 47% female) or BNT (n=532, 40% female). In ChAd-primed participants, geometric mean concentration (GMC) 28 days after a boost of SARS-CoV-2 anti-spike IgG in recipients of ChAd/m1273 (20 114 ELISA laboratory units [ELU]/mL [95% CI 18 160 to 22 279]) and ChAd/NVX (5597 ELU/mL [4756 to 6586]) was non-inferior to that of ChAd/ChAd recipients (1971 ELU/mL [1718 to 2262]) with a GMR of 10·2 (one-sided 98·75% CI 8·4 to ∞) for ChAd/m1273 and 2·8 (2·2 to ∞) for ChAd/NVX, compared with ChAd/ChAd. In BNT-primed participants, non-inferiority was shown for BNT/m1273 (GMC 22 978 ELU/mL [95% CI 20 597 to 25 636]) but not for BNT/NVX (8874 ELU/mL [7391 to 10 654]), compared with BNT/BNT (16 929 ELU/mL [15 025 to 19 075]) with a GMR of 1·3 (one-sided 98·75% CI 1·1 to ∞) for BNT/m1273 and 0·5 (0·4 to ∞) for BNT/NVX, compared with BNT/BNT; however, NVX still induced an 18-fold rise in GMC 28 days after vaccination. There were 15 serious adverse events, none considered related to immunisation.

Interpretation: heterologous second dosing with m1273, but not NVX, increased transient systemic reactogenicity compared with homologous schedules. Multiple vaccines are appropriate to complete primary immunisation following priming with BNT or ChAd, facilitating rapid vaccine deployment globally and supporting recognition of such schedules for vaccine certification.

Funding: UK Vaccine Task Force, Coalition for Epidemic Preparedness Innovations (CEPI), and National Institute for Health Research. NVX vaccine was supplied for use in the trial by Novavax.

Text
1-s2.0-S0140673621027185-main - Version of Record
Available under License Other.
Download (1MB)

More information

e-pub ahead of print date: 6 December 2021
Published date: 1 January 2022
Additional Information: Funding Information: The study is funded by the UK Government through the National Institute for Health Research, the Vaccine Task Force, and the Coalition for Epidemic Preparedness Innovations. This research was supported by the NIHR Oxford Biomedical Research Centre, NIHR Guy's and St Thomas' Biomedical Research Centre, NIHR King's Clinical Research Facility and NIHR Policy Research Programme (PR-R17-0916-22001), the Southampton NIHR Biomedical Research Centre and Southampton NIHR Clinical Research Facility and delivered through the NIHR-funded National Immunisation Schedule Evaluation Consortium. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. NVX vaccine was supplied for use in the trial by Novavax. MDS and SNF are NIHR senior investigators. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The investigators express their gratitude for the contribution of all trial participants, and for the invaluable advice of the data safety monitoring board. We additionally acknowledge the broader support from the various teams within the University of Oxford, including the Department of Paediatrics, Clinical Trials Research Governance, Research Contracts, and the Public Affairs Directorate. Funding Information: MDS acts on behalf of the University of Oxford as an investigator on studies funded or sponsored by vaccine manufacturers, including AstraZeneca, GlaxoSmithKline, Pfizer, Novavax, Janssen, Medimmune, and MCM. He receives no personal financial payment for this work. JSN-V-T is seconded to the Department of Health and Social Care, England. AMC and DMF are investigators on studies funded by Pfizer and Unilever. They receive no personal financial payment for this work. AF is a member of the Joint Committee on Vaccination and Immunisation and chair of the WHO European Technical Advisory Group of Experts on Immunisation. He is an investigator or provides consultative advice on clinical trials and studies of COVID-19 vaccines produced by AstraZeneca, Janssen, Valneva, Pfizer, and Sanofi, and of other vaccines from these and other manufacturers, including GlaxoSmithKline, VPI Pharmaceuticals, Takeda, and Bionet Asia. He receives no personal remuneration or benefits for any of this work. SNF acts on behalf of University Hospital Southampton NHS Foundation Trust as an investigator or provides consultative advice on clinical trials and studies of COVID-19 and other vaccines funded or sponsored by vaccine manufacturers, including Janssen, Pfizer, AstraZeneca, GlaxoSmithKline, Novavax, Seqirus, Sanofi, Medimmune, Merck, and Valneva. He receives no personal financial payment for this work. PTH acts on behalf of St George's University of London as an investigator on clinical trials of COVID-19 vaccines funded or sponsored by vaccine manufacturers, including Janssen, Pfizer, AstraZeneca, Novavax, and Valneva. He receives no personal financial payment for this work. CAG acts on behalf of University Hospitals Birmingham NHS Foundation Trust as an investigator on clinical trials and studies of COVID-19 and other vaccines funded or sponsored by vaccine manufacturers, including Janssen, Pfizer, AstraZeneca, Novavax, CureVac, Moderna, and Valneva. He receives no personal financial payment for this work. VL acts on behalf of University College London Hospitals NHS Foundation Trust as an investigator on clinical trials of COVID-19 vaccines funded or sponsored by vaccine manufacturers including Pfizer, AstraZeneca, and Valneva. He receives no personal financial payment for this work. TL is named as an inventor on a patent application covering the ChAd vaccine and is an occasional consultant to Vaccitech, unrelated to this work. ALG is named as an inventor on a patent covering use of a particular promoter construct that is often used in ChAdOx1-vectored vaccines and is incorporated in the ChAdOx1 nCoV-19 vaccine. ALG benefits from royalty income paid to the University of Oxford from sales of this vaccine by AstraZeneca and its sublicensees under the University's revenue sharing policy. Oxford University has entered into a partnership with AstraZeneca for further development of ChAdOx1 nCoV-19. All other authors declare no competing interests.

Identifiers

Local EPrints ID: 454076
URI: http://eprints.soton.ac.uk/id/eprint/454076
ISSN: 0140-6736
PURE UUID: 29acc976-8e4f-4072-a3b6-41ef1f862208
ORCID for Saul N Faust: ORCID iD orcid.org/0000-0003-3410-7642
ORCID for Robert C Read: ORCID iD orcid.org/0000-0002-4297-6728

Catalogue record

Date deposited: 28 Jan 2022 17:31
Last modified: 16 Aug 2024 01:45

Export record

Altmetrics

Contributors

Author: Arabella S V Stuart
Author: Robert H Shaw
Author: Xinxue Liu
Author: Melanie Greenland
Author: Parvinder K Aley
Author: Nick J Andrews
Author: J C Cameron
Author: Sue Charlton
Author: Elizabeth A Clutterbuck
Author: Andrea M Collins
Author: Tom Darton
Author: Tanya Dinesh
Author: Christopher J A Duncan
Author: Anna England
Author: Saul N Faust ORCID iD
Author: Daniela M Ferreira
Author: Adam Finn
Author: Anna L Goodman
Author: Christopher A Green
Author: Bassam Hallis
Author: Paul T Heath
Author: Helen Hill
Author: Bryn M Horsington
Author: Teresa Lambe
Author: Rajeka Lazarus
Author: Vincenzo Libri
Author: Patrick J Lillie
Author: Yama F Mujadidi
Author: Ruth Payne
Author: Emma L Plested
Author: Samuel Provstgaard-Morys
Author: Maheshi N Ramasamy
Author: Mary Ramsay
Author: Robert C Read ORCID iD
Author: Hannah Robinson
Author: Gavin R Screaton
Author: Nisha Singh
Author: David P J Turner
Author: Paul J Turner
Author: Iason Vichos
Author: Rachel White
Author: Jonathan S Nguyen-Van-Tam
Author: Matthew D Snape
Corporate Author: Com-COV2 Study Group

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×